These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31416604)

  • 1. Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty/minicircle vector into NK-92MI cells for treatment of pancreatic cancer.
    Batchu RB; Gruzdyn OV; Tavva PS; Kolli BK; Dachepalli R; Weaver DW; Gruber SA
    Surgery; 2019 Oct; 166(4):503-508. PubMed ID: 31416604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro.
    Batchu RB; Gruzdyn OV; Mahmud EM; Chukr F; Dachepalli R; Manmari SK; Mostafa G; Weaver DW; Gruber SA
    Surgery; 2018 Mar; 163(3):627-632. PubMed ID: 29336814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer.
    Makita Y; Kunii N; Sakurai D; Ihara F; Motohashi S; Suzuki A; Nakayama T; Okamoto Y
    BMC Cancer; 2018 Dec; 18(1):1254. PubMed ID: 30558663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.
    Ko AH; Jordan AC; Tooker E; Lacey SF; Chang RB; Li Y; Venook AP; Tempero M; Damon L; Fong L; O'Hara MH; Levine BL; Melenhorst JJ; Plesa G; June CH; Beatty GL
    Mol Ther; 2020 Nov; 28(11):2367-2378. PubMed ID: 32730744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
    Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
    Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
    Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer.
    He J; Zhang Z; Lv S; Liu X; Cui L; Jiang D; Zhang Q; Li L; Qin W; Jin H; Qian Q
    Cell Immunol; 2018 Jul; 329():31-40. PubMed ID: 29859625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton radiation boosts the efficacy of mesothelin-targeting chimeric antigen receptor T cell therapy in pancreatic cancer.
    Amit U; Uslu U; Verginadis II; Kim MM; Motlagh SAO; Diffenderfer ES; Assenmacher CA; Bicher S; Atoche SJ; Ben-Josef E; Young RM; June CH; Koumenis C
    Proc Natl Acad Sci U S A; 2024 Jul; 121(31):e2403002121. PubMed ID: 39047033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
    Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
    Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.
    Hung CF; Xu X; Li L; Ma Y; Jin Q; Viley A; Allen C; Natarajan P; Shivakumar R; Peshwa MV; Emens LA
    Hum Gene Ther; 2018 May; 29(5):614-625. PubMed ID: 29334771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Killing Effect of A CD7 Chimeric Antigen Receptor-Modified NK-92MI Cell Line on CD7-Positive Hematological Malignant Cells].
    Zhu XY; Liu X; Wang XB; Wang AY; Wang M; Liu NN; You FT; Pan GF; Yang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1367-1375. PubMed ID: 32798428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.
    Jiang H; Zhang W; Shang P; Zhang H; Fu W; Ye F; Zeng T; Huang H; Zhang X; Sun W; Man-Yuen Sze D; Yi Q; Hou J
    Mol Oncol; 2014 Mar; 8(2):297-310. PubMed ID: 24388357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
    JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
    Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
    Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System.
    Bauser M; Einsele H; Löffler J; Hudecek M; Seif M
    J Vis Exp; 2024 Oct; (212):. PubMed ID: 39431788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.
    Bexte T; Botezatu L; Miskey C; Gierschek F; Moter A; Wendel P; Reindl LM; Campe J; Villena-Ossa JF; Gebel V; Stein K; Cathomen T; Cremer A; Wels WS; Hudecek M; Ivics Z; Ullrich E
    Mol Ther; 2024 Jul; 32(7):2357-2372. PubMed ID: 38751112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
    Mehta RS; Rezvani K
    Front Immunol; 2018; 9():283. PubMed ID: 29497427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
    Haas AR; Tanyi JL; O'Hara MH; Gladney WL; Lacey SF; Torigian DA; Soulen MC; Tian L; McGarvey M; Nelson AM; Farabaugh CS; Moon E; Levine BL; Melenhorst JJ; Plesa G; June CH; Albelda SM; Beatty GL
    Mol Ther; 2019 Nov; 27(11):1919-1929. PubMed ID: 31420241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer.
    Tarannum M; Dinh K; Vergara J; Birch G; Abdulhamid YZ; Kaplan IE; Ay O; Maia A; Beaver O; Sheffer M; Shapiro R; Ali AK; Dong H; Ham JD; Bobilev E; James S; Cameron AB; Nguyen QD; Ganapathy S; Chayawatto C; Koreth J; Paweletz CP; Gokhale PC; Barbie DA; Matulonis UA; Soiffer RJ; Ritz J; Porter RL; Chen J; Romee R
    Sci Adv; 2024 Jul; 10(28):eadn0881. PubMed ID: 38996027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.